{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,3]],"date-time":"2026-10-03T03:17:10Z","timestamp":1790997430356,"version":"4.1.0"},"reference-count":64,"publisher":"Elsevier BV","issue":"3","license":[{"start":{"date-parts":[[2026,3,1]],"date-time":"2026-03-01T00:00:00Z","timestamp":1772323200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2026,3,1]],"date-time":"2026-03-01T00:00:00Z","timestamp":1772323200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2025,10,10]],"date-time":"2025-10-10T00:00:00Z","timestamp":1760054400000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0\/"}],"funder":[{"DOI":"10.13039\/501100001809","name":"National Natural Science Foundation of China","doi-asserted-by":"publisher","award":["81773179"],"award-info":[{"award-number":["81773179"]}],"id":[{"id":"10.13039\/501100001809","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100001809","name":"National Natural Science Foundation of China","doi-asserted-by":"publisher","award":["82204262"],"award-info":[{"award-number":["82204262"]}],"id":[{"id":"10.13039\/501100001809","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100001809","name":"National Natural Science Foundation of China","doi-asserted-by":"publisher","award":["2204262"],"award-info":[{"award-number":["2204262"]}],"id":[{"id":"10.13039\/501100001809","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100019091","name":"Key Research and Development Program of Hunan Province of China","doi-asserted-by":"publisher","award":["2022SK2055"],"award-info":[{"award-number":["2022SK2055"]}],"id":[{"id":"10.13039\/501100019091","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100004735","name":"Hunan Provincial Natural Science Foundation","doi-asserted-by":"publisher","award":["2023JJ30733"],"award-info":[{"award-number":["2023JJ30733"]}],"id":[{"id":"10.13039\/501100004735","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100004735","name":"Hunan Provincial Natural Science Foundation","doi-asserted-by":"publisher","award":["2020JJ4771"],"award-info":[{"award-number":["2020JJ4771"]}],"id":[{"id":"10.13039\/501100004735","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100000001","name":"National Science Foundation","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100000001","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Acta Pharmaceutica Sinica B"],"published-print":{"date-parts":[[2026,3]]},"DOI":"10.1016\/j.apsb.2025.10.007","type":"journal-article","created":{"date-parts":[[2025,10,15]],"date-time":"2025-10-15T16:50:03Z","timestamp":1760547003000},"page":"1584-1604","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":4,"title":["A triple combination strategy for nasopharyngeal carcinoma: Aptamer-guided liposomal chemotherapy, engineered NK cells, and Fc-enhanced PD-L1 antibody therapy"],"prefix":"10.1016","volume":"16","author":[{"given":"Chaoyan","family":"Yao","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Lei","family":"Wang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Weidong","family":"Liu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ning","family":"Shi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ziling","family":"Liao","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yuxuan","family":"Fu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jinhao","family":"Ouyang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Xuan","family":"Lei","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Qianping","family":"Huang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Siyu","family":"Li","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yihua","family":"Zhouyang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Pinnan","family":"Zhao","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jie","family":"Wang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hongjuan","family":"Xu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Wenhu","family":"Zhou","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Xingjun","family":"Jiang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Xiang","family":"Gao","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Caiping","family":"Ren","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-8307-6478","authenticated-orcid":false,"given":"Longlong","family":"Luo","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.apsb.2025.10.007_bib1","doi-asserted-by":"crossref","first-page":"64","DOI":"10.1016\/S0140-6736(19)30956-0","article-title":"Nasopharyngeal carcinoma","volume":"394","author":"Chen","year":"2019","journal-title":"Lancet"},{"key":"10.1016\/j.apsb.2025.10.007_bib2","doi-asserted-by":"crossref","DOI":"10.1016\/j.jdent.2025.105583","article-title":"Burden of nasopharyngeal carcinoma in Asia from 1990 to 2021","volume":"154","author":"Cui","year":"2025","journal-title":"J Dent"},{"key":"10.1016\/j.apsb.2025.10.007_bib3","doi-asserted-by":"crossref","first-page":"14","DOI":"10.1016\/j.jmgm.2006.09.005","article-title":"The intercalation of DNA double helices with doxorubicin and nogalamycin","volume":"26","author":"Box","year":"2007","journal-title":"J Mol Graph Model"},{"key":"10.1016\/j.apsb.2025.10.007_bib4","doi-asserted-by":"crossref","first-page":"15182","DOI":"10.1073\/pnas.1922072117","article-title":"Uncoupling DNA damage from chromatin damage to detoxify doxorubicin","volume":"117","author":"Qiao","year":"2020","journal-title":"Proc Natl Acad Sci U S A"},{"key":"10.1016\/j.apsb.2025.10.007_bib5","doi-asserted-by":"crossref","DOI":"10.1016\/j.intimp.2024.113373","article-title":"Molecular signaling pathways in doxorubicin-induced nephrotoxicity and potential therapeutic agents","volume":"144","author":"Lu","year":"2025","journal-title":"Int Immunopharmacol"},{"key":"10.1016\/j.apsb.2025.10.007_bib6","doi-asserted-by":"crossref","first-page":"1040","DOI":"10.3892\/etm.2014.1535","article-title":"Prevention of adriamycin-induced hepatic and renal toxicity in male BALB\/c mice by a nutrient mixture","volume":"7","author":"Roomi","year":"2014","journal-title":"Exp Ther Med"},{"key":"10.1016\/j.apsb.2025.10.007_bib7","doi-asserted-by":"crossref","DOI":"10.1002\/cmdc.202400938","article-title":"Advances in lipid nanoparticle-based disease treatment","volume":"20","author":"Zhou","year":"2025","journal-title":"ChemMedChem"},{"key":"10.1016\/j.apsb.2025.10.007_bib8","doi-asserted-by":"crossref","first-page":"36","DOI":"10.3390\/pharmaceutics17010036","article-title":"Liposomal formulations: a recent update","volume":"17","author":"Agrawal","year":"2024","journal-title":"Pharmaceutics"},{"key":"10.1016\/j.apsb.2025.10.007_bib9","doi-asserted-by":"crossref","DOI":"10.1155\/2021\/3041969","article-title":"Investigating the application of liposomes as drug delivery systems for the diagnosis and treatment of cancer","volume":"2021","author":"Allahou","year":"2021","journal-title":"Int J Biomater"},{"key":"10.1016\/j.apsb.2025.10.007_bib10","doi-asserted-by":"crossref","DOI":"10.1016\/j.addr.2022.114449","article-title":"Strategies to enhance drug delivery to solid tumors by harnessing the EPR effects and alternative targeting mechanisms","volume":"188","author":"Zi","year":"2022","journal-title":"Adv Drug Deliv Rev"},{"key":"10.1016\/j.apsb.2025.10.007_bib11","doi-asserted-by":"crossref","first-page":"653","DOI":"10.1038\/nrclinonc.2010.139","article-title":"Delivering nanomedicine to solid tumors","volume":"7","author":"Jain","year":"2010","journal-title":"Nat Rev Clin Oncol"},{"key":"10.1016\/j.apsb.2025.10.007_bib12","doi-asserted-by":"crossref","first-page":"583","DOI":"10.1038\/nrc1893","article-title":"Drug penetration in solid tumours","volume":"6","author":"Minchinton","year":"2006","journal-title":"Nat Rev Cancer"},{"key":"10.1016\/j.apsb.2025.10.007_bib13","doi-asserted-by":"crossref","first-page":"55328","DOI":"10.18632\/oncotarget.10530","article-title":"CD109 is identified as a potential nasopharyngeal carcinoma biomarker using aptamer selected by cell-SELEX","volume":"7","author":"Jia","year":"2016","journal-title":"Oncotarget"},{"key":"10.1016\/j.apsb.2025.10.007_bib14","doi-asserted-by":"crossref","first-page":"79","DOI":"10.1186\/s40463-023-00673-2","article-title":"The effects of doxorubicin loaded aptamer S3-linked DNA tetrahedrons on nasopharyngeal carcinoma","volume":"52","author":"Liu","year":"2023","journal-title":"J Otolaryngol Head Neck Surg"},{"key":"10.1016\/j.apsb.2025.10.007_bib15","doi-asserted-by":"crossref","first-page":"487","DOI":"10.1038\/nrd4506","article-title":"Therapeutic approaches to enhance natural killer cell cytotoxicity against cancer: the force awakens","volume":"14","author":"Childs","year":"2015","journal-title":"Nat Rev Drug Discov"},{"key":"10.1016\/j.apsb.2025.10.007_bib16","doi-asserted-by":"crossref","first-page":"37","DOI":"10.1016\/j.smim.2017.07.009","article-title":"NK cell-based immunotherapy for cancer","volume":"31","author":"Fang","year":"2017","journal-title":"Semin Immunol"},{"key":"10.1016\/j.apsb.2025.10.007_bib17","doi-asserted-by":"crossref","first-page":"4129","DOI":"10.3390\/cancers13164129","article-title":"NK cell therapy: a rising star in cancer treatment","volume":"13","author":"Du","year":"2021","journal-title":"Cancers (Basel)"},{"key":"10.1016\/j.apsb.2025.10.007_bib18","doi-asserted-by":"crossref","first-page":"164","DOI":"10.3390\/ijms23010164","article-title":"Challenges and recent advances in NK cell-targeted immunotherapies in solid tumors","volume":"23","author":"Lian","year":"2021","journal-title":"Int J Mol Sci"},{"key":"10.1016\/j.apsb.2025.10.007_bib19","doi-asserted-by":"crossref","DOI":"10.1111\/cpr.13791","article-title":"Revolutionising cancer immunotherapy: advancements and prospects in non-viral CAR-NK cell engineering","volume":"58","author":"Zhou","year":"2025","journal-title":"Cell Prolif"},{"key":"10.1016\/j.apsb.2025.10.007_bib20","doi-asserted-by":"crossref","first-page":"536","DOI":"10.1158\/1535-7163.MCT-24-0721","article-title":"Unlocking the potential of CAR-NK cell therapy: overcoming barriers and challenges in the treatment of myeloid malignancies","volume":"24","author":"Zhang","year":"2025","journal-title":"Mol Cancer Ther"},{"key":"10.1016\/j.apsb.2025.10.007_bib21","doi-asserted-by":"crossref","DOI":"10.1038\/mtna.2014.32","article-title":"Oligonucleotide aptamers: new tools for targeted cancer therapy","volume":"3","author":"Sun","year":"2014","journal-title":"Mol Ther Nucleic Acids"},{"key":"10.1016\/j.apsb.2025.10.007_bib22","doi-asserted-by":"crossref","first-page":"3262","DOI":"10.1021\/acs.analchem.7b04775","article-title":"Strategy for generating sequence-defined aptamer reagent sets for detecting protein contaminants in biotherapeutics","volume":"90","author":"Jbt","year":"2018","journal-title":"Anal Chem"},{"key":"10.1016\/j.apsb.2025.10.007_bib23","doi-asserted-by":"crossref","first-page":"164","DOI":"10.1016\/j.omtn.2018.08.023","article-title":"Oligonucleotide aptamer-mediated precision therapy of hematological malignancies","volume":"13","author":"Yang","year":"2018","journal-title":"Mol Ther Nucleic Acids"},{"key":"10.1016\/j.apsb.2025.10.007_bib24","article-title":"Aptamer-engineered natural killer cells for cell-specific adaptive immunotherapy","volume":"15","author":"Yang","year":"2019","journal-title":"Small"},{"key":"10.1016\/j.apsb.2025.10.007_bib25","doi-asserted-by":"crossref","first-page":"164","DOI":"10.1007\/s12672-023-00780-6","article-title":"Natural killer cells modified with a Gpc3 aptamer enhance adoptive immunotherapy for hepatocellular carcinoma","volume":"14","author":"Zheng","year":"2023","journal-title":"Discov Oncol"},{"key":"10.1016\/j.apsb.2025.10.007_bib26","doi-asserted-by":"crossref","first-page":"935","DOI":"10.1080\/17512433.2017.1356717","article-title":"Atezolizumab for the treatment of non-small cell lung cancer","volume":"10","author":"Santini","year":"2017","journal-title":"Expert Rev Clin Pharmacol"},{"key":"10.1016\/j.apsb.2025.10.007_bib27","doi-asserted-by":"crossref","first-page":"269","DOI":"10.1080\/21645515.2017.1403694","article-title":"Product review on the anti-PD-L1 antibody atezolizumab","volume":"14","author":"Shah","year":"2018","journal-title":"Hum Vaccin Immunother"},{"key":"10.1016\/j.apsb.2025.10.007_bib28","doi-asserted-by":"crossref","first-page":"64","DOI":"10.3390\/antib9040064","article-title":"Fc-engineering for modulated effector functions-improving antibodies for cancer treatment","volume":"9","author":"Liu","year":"2020","journal-title":"Antibodies"},{"key":"10.1016\/j.apsb.2025.10.007_bib29","article-title":"The Fc-effector function of CIVID-19 convalescent plasma contributes to SARS-CoV-2 treatment efficacy in mice","volume":"4","author":"Ullah","year":"2023","journal-title":"Cell Rep Med"},{"key":"10.1016\/j.apsb.2025.10.007_bib30","doi-asserted-by":"crossref","first-page":"381","DOI":"10.1038\/s41577-022-00813-1","article-title":"Beyond neutralization: Fc-dependent antibody effector functions in SARS-CoV-2 infection","volume":"23","author":"Zhang","year":"2023","journal-title":"Nat Rev Immunol"},{"key":"10.1016\/j.apsb.2025.10.007_bib31","doi-asserted-by":"crossref","first-page":"46697","DOI":"10.1021\/acsami.3c10364","article-title":"Doxorubicin-loaded liposome with the function of \"killing two birds with one stone\" against glioma","volume":"15","author":"Cen","year":"2023","journal-title":"ACS Appl Mater Interfaces"},{"key":"10.1016\/j.apsb.2025.10.007_bib32","doi-asserted-by":"crossref","first-page":"195","DOI":"10.1080\/10717544.2020.1870583","article-title":"A novel redox-responsive ursolic acid polymeric prodrug delivery system for osteosarcoma therapy","volume":"28","author":"Fu","year":"2021","journal-title":"Drug Deliv"},{"key":"10.1016\/j.apsb.2025.10.007_bib33","doi-asserted-by":"crossref","first-page":"265","DOI":"10.1016\/j.jconrel.2020.07.022","article-title":"Acid-sensitive PEGylated paclitaxel prodrug nanoparticles for cancer therapy: effect of peg length on antitumor efficacy","volume":"326","author":"Mu","year":"2020","journal-title":"J Control Release"},{"key":"10.1016\/j.apsb.2025.10.007_bib34","article-title":"Nasopharyngeal carcinoma and its microenvironment: past, current, and future perspectives","volume":"12","author":"Su","year":"2022","journal-title":"Front Oncol"},{"key":"10.1016\/j.apsb.2025.10.007_bib35","first-page":"4707","article-title":"Platinum-crosslinking polymeric nanoparticle for synergetic chemoradiotherapy of nasopharyngeal carcinoma","volume":"6","author":"Ding","year":"2021","journal-title":"Bioact Mater"},{"key":"10.1016\/j.apsb.2025.10.007_bib36","doi-asserted-by":"crossref","DOI":"10.1002\/ctm2.1315","article-title":"Single-cell analysis reveals the multiple patterns of immune escape in the nasopharyngeal carcinoma microenvironment","volume":"13","author":"Lin","year":"2023","journal-title":"Clin Transl Med"},{"key":"10.1016\/j.apsb.2025.10.007_bib37","doi-asserted-by":"crossref","DOI":"10.1002\/adma.201907568","article-title":"Selenium-containing nanoparticles combine the NK cells mediated immunotherapy with radiotherapy and chemotherapy","volume":"32","author":"Gao","year":"2020","journal-title":"Adv Mater"},{"key":"10.1016\/j.apsb.2025.10.007_bib38","doi-asserted-by":"crossref","first-page":"3421","DOI":"10.1021\/acs.nanolett.4c00002","article-title":"Programmed remodeling of the tumor milieu to enhance NK cell immunotherapy combined with chemotherapy for pancreatic cancer","volume":"24","author":"Yang","year":"2024","journal-title":"Nano Lett"},{"key":"10.1016\/j.apsb.2025.10.007_bib39","doi-asserted-by":"crossref","DOI":"10.4028\/b-wjQRP6","article-title":"Broad-spectrum engineered multivalent nanobodies against SARS-CoV-1\/2","volume":"11","author":"Wang","year":"2024","journal-title":"Adv Sci (Weinh)"},{"key":"10.1016\/j.apsb.2025.10.007_bib40","article-title":"In situ cancer vaccination using lipidoid nanoparticles","volume":"7","author":"Chen","year":"2021","journal-title":"Sci Adv"},{"key":"10.1016\/j.apsb.2025.10.007_bib41","article-title":"Immunogenic cell death-based cancer vaccines: promising prospect in cancer therapy","volume":"15","author":"Wang","year":"2024","journal-title":"Front Immunol"},{"key":"10.1016\/j.apsb.2025.10.007_bib42","doi-asserted-by":"crossref","first-page":"659","DOI":"10.3390\/cells12040659","article-title":"Doxorubicin-an agent with multiple mechanisms of anticancer activity","volume":"12","author":"Kciuk","year":"2023","journal-title":"Cells"},{"key":"10.1016\/j.apsb.2025.10.007_bib43","doi-asserted-by":"crossref","DOI":"10.1038\/s41598-021-91603-7","article-title":"Chemoradiation induces upregulation of immunogenic cell death-related molecules together with increased expression of PD-L1 and galectin-9 in gastric cancer","volume":"11","author":"Petersen","year":"2021","journal-title":"Sci Rep"},{"key":"10.1016\/j.apsb.2025.10.007_bib44","doi-asserted-by":"crossref","first-page":"21","DOI":"10.1016\/j.bbmt.2020.09.030","article-title":"NK cell adoptive immunotherapy of cancer: evaluating recognition strategies and overcoming limitations","volume":"27","author":"Sanchez","year":"2021","journal-title":"Transplant Cell Ther"},{"key":"10.1016\/j.apsb.2025.10.007_bib45","doi-asserted-by":"crossref","first-page":"315","DOI":"10.1038\/s41423-024-01145-x","article-title":"Development of NK cell-based cancer immunotherapies through receptor engineering","volume":"21","author":"Page","year":"2024","journal-title":"Cell Mol Immunol"},{"key":"10.1016\/j.apsb.2025.10.007_bib46","doi-asserted-by":"crossref","first-page":"12022","DOI":"10.1002\/anie.202002145","article-title":"Equipping natural killer cells with specific targeting and checkpoint blocking aptamers for enhanced adoptive immunotherapy in solid tumors","volume":"59","author":"Zhang","year":"2020","journal-title":"Angew Chem Int Ed Engl"},{"key":"10.1016\/j.apsb.2025.10.007_bib47","doi-asserted-by":"crossref","DOI":"10.1002\/smll.201970228","article-title":"Artificial engineered natural killer cells combined with antiheat endurance as a powerful strategy for enhancing photothermal-immunotherapy efficiency of solid tumors","volume":"15","author":"Zhang","year":"2019","journal-title":"Small"},{"key":"10.1016\/j.apsb.2025.10.007_bib48","article-title":"Engineering of a multi-modular DNA nanodevice for spatioselective imaging and evaluation of NK cell-mediated cancer immunotherapy","volume":"64","author":"Chen","year":"2025","journal-title":"Angew Chem Int Ed Engl"},{"key":"10.1016\/j.apsb.2025.10.007_bib49","doi-asserted-by":"crossref","DOI":"10.1016\/j.biomaterials.2021.121259","article-title":"Targeted immunotherapy of triple-negative breast cancer by aptamer-engineered NK cells","volume":"280","author":"Chen","year":"2022","journal-title":"Biomaterials"},{"key":"10.1016\/j.apsb.2025.10.007_bib50","doi-asserted-by":"crossref","first-page":"632","DOI":"10.1016\/j.apsb.2022.08.006","article-title":"Anti-PD-L1 antibody enhances curative effect of cryoablation via antibody-dependent cell-mediated cytotoxicity mediating PD-L1highCD11b+ cells elimination in hepatocellular carcinoma","volume":"13","author":"Tan","year":"2023","journal-title":"Acta Pharm Sin B"},{"key":"10.1016\/j.apsb.2025.10.007_bib51","doi-asserted-by":"crossref","DOI":"10.1136\/jitc-2020-000873","article-title":"Anti-tumor effects of NK cells and anti-PD-L1 antibody with antibody-dependent cellular cytotoxicity in PD-L1-positive cancer cell lines","volume":"8","author":"Park","year":"2020","journal-title":"J Immunother Cancer"},{"key":"10.1016\/j.apsb.2025.10.007_bib52","doi-asserted-by":"crossref","first-page":"2140","DOI":"10.3389\/fimmu.2018.02140","article-title":"Avelumab, an IgG1 anti-PD-L1 immune checkpoint inhibitor, triggers NK cell-mediated cytotoxicity and cytokine production against triple negative breast cancer cells","volume":"9","author":"Juli\u00e1","year":"2018","journal-title":"Front Immunol"},{"key":"10.1016\/j.apsb.2025.10.007_bib53","doi-asserted-by":"crossref","first-page":"1415","DOI":"10.3390\/cells11091415","article-title":"Immunogenic cell death, DAMPs and prothymosin \u03b1 as a putative anticancer immune response biomarker","volume":"11","author":"Birmpilis","year":"2022","journal-title":"Cells"},{"key":"10.1016\/j.apsb.2025.10.007_bib54","doi-asserted-by":"crossref","DOI":"10.3389\/fimmu.2022.1017400","article-title":"Research progress in inducing immunogenic cell death of tumor cells","volume":"13","author":"Xie","year":"2022","journal-title":"Front Immunol"},{"key":"10.1016\/j.apsb.2025.10.007_bib55","doi-asserted-by":"crossref","first-page":"1211","DOI":"10.1016\/j.apsb.2024.06.004","article-title":"Intravenous delivery of STING agonists using acid-sensitive polycationic polymer-modified lipid nanoparticles for enhanced tumor immunotherapy","volume":"15","author":"He","year":"2025","journal-title":"Acta Pharm Sin B"},{"key":"10.1016\/j.apsb.2025.10.007_bib56","doi-asserted-by":"crossref","first-page":"216","DOI":"10.1038\/s41419-019-1459-7","article-title":"Cryo-thermal therapy induces macrophage polarization for durable anti-tumor immunity","volume":"10","author":"He","year":"2019","journal-title":"Cell Death Dis"},{"key":"10.1016\/j.apsb.2025.10.007_bib57","doi-asserted-by":"crossref","first-page":"275","DOI":"10.1038\/s41419-025-07610-3","article-title":"The transition between M1 and M2 macrophage phenotypes is associated with the disease status following CD19 CAR-T therapy for B cell lymphoma\/leukemia","volume":"16","author":"Zhao","year":"2025","journal-title":"Cell Death Dis"},{"key":"10.1016\/j.apsb.2025.10.007_bib58","doi-asserted-by":"crossref","DOI":"10.1016\/j.biomaterials.2025.123287","article-title":"M1-macrophage membrane-camouflaged nanoframeworks activate multiple immunity via calcium overload and photo-sonosensitization","volume":"320","author":"Shen","year":"2025","journal-title":"Biomaterials"},{"key":"10.1016\/j.apsb.2025.10.007_bib59","doi-asserted-by":"crossref","first-page":"890","DOI":"10.1038\/s41467-025-56134-z","article-title":"Hypoxia-tropic delivery of nanozymes targeting transferrin receptor 1 for nasopharyngeal carcinoma radiotherapy sensitization","volume":"16","author":"Zhang","year":"2025","journal-title":"Nat Commun"},{"key":"10.1016\/j.apsb.2025.10.007_bib60","doi-asserted-by":"crossref","first-page":"67","DOI":"10.1186\/s12943-025-02272-3","article-title":"Circular RNA circCLASP2 promotes nasopharyngeal carcinoma progression through binding to DHX9 to enhance PCMT1 translation","volume":"24","author":"Peng","year":"2025","journal-title":"Mol Cancer"},{"key":"10.1016\/j.apsb.2025.10.007_bib61","doi-asserted-by":"crossref","DOI":"10.1136\/jitc-2024-010301","article-title":"Acetyltransferase NAT10 Inhibits T-cell immunity and promotes nasopharyngeal carcinoma progression through DDX5\/HMGB1 axis","volume":"13","author":"Xie","year":"2025","journal-title":"J Immunother Cancer"},{"key":"10.1016\/j.apsb.2025.10.007_bib62","doi-asserted-by":"crossref","DOI":"10.1080\/2162402X.2019.1624128","article-title":"Atezolizumab potentiates T cell-mediated cytotoxicity and coordinates with FAK to suppress cell invasion and motility in PD-L1+ triple negative breast cancer cells","volume":"8","author":"Mohan","year":"2019","journal-title":"OncoImmunology"},{"key":"10.1016\/j.apsb.2025.10.007_bib63","first-page":"82","article-title":"Role of PD-1\/PD-L1 signaling axis in oncogenesis and its targeting by bioactive natural compounds for cancer immunotherapy","volume":"11","author":"Godiyal","year":"2024","journal-title":"Mil Med Res"},{"key":"10.1016\/j.apsb.2025.10.007_bib64","doi-asserted-by":"crossref","first-page":"146","DOI":"10.1038\/cmi.2016.38","article-title":"Selection and characterization of the novel anti-human PD-1 FV78 antibody from a targeted epitope mammalian cell-displayed antibody library","volume":"15","author":"Luo","year":"2018","journal-title":"Cell Mol Immunol"}],"container-title":["Acta Pharmaceutica Sinica B"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S221138352500680X?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S221138352500680X?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2026,4,13]],"date-time":"2026-04-13T00:31:56Z","timestamp":1776040316000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S221138352500680X"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,3]]},"references-count":64,"journal-issue":{"issue":"3","published-print":{"date-parts":[[2026,3]]}},"alternative-id":["S221138352500680X"],"URL":"https:\/\/doi.org\/10.1016\/j.apsb.2025.10.007","relation":{},"ISSN":["2211-3835"],"issn-type":[{"value":"2211-3835","type":"print"}],"subject":[],"published":{"date-parts":[[2026,3]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"A triple combination strategy for nasopharyngeal carcinoma: Aptamer-guided liposomal chemotherapy, engineered NK cells, and Fc-enhanced PD-L1 antibody therapy","name":"articletitle","label":"Article Title"},{"value":"Acta Pharmaceutica Sinica B","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.apsb.2025.10.007","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2025 The Authors. Published by Elsevier B.V. on behalf of Chinese Pharmaceutical Association and Institute of Materia Medica, Chinese Academy of Medical Sciences.","name":"copyright","label":"Copyright"}]}}